International Consultant
Run-Lin Gao M.D.   Academician of the Chinese Academy of Engineering

    Dr. Gao is the principal investigator of all the clinical trials for NeucardinTM that have been conducted in China. He worked as the head of the Cardiovascular Disease Institute of the Chinese Academy of Medical Sciences and Fuwai Hospital, and is now taking responsibility as the Vice Chairman of the Chinese Doctor Association, Standing Director of the Chinese Medical Association, FACC, and Chief Editor of the Chinese Medical Journal. Professor Gao was the first to perform emergency percutaneous transluminal coronary angioplasty for acute myocardial infarction and the first to report the use of coronary stenting and drug-eluting stents in China. He has received seven academic awards, and has more than 490 original publications.

Professor Paul M. Vanhoutte
    Dr. Vanhoutte is the former president of the International Union of Pharmacology (IUPHAR). Dr. Vanhoutte serves as the Editor-in-Chief of the Journal of Cardiovascular Pharmacology, as an advisor to the Ministry of Science and Technology of the People's Republic of China, and as Vice President of R&D of an international research organization in France. His academic career took him from the University of Ghent to the University of Antwerp, the Mayo Medical School, and Baylor College of Medicine. He is currently a Distinguished Visiting Professor, and Director of the Biopharmaceutical Development Centre, at the University of Hong Kong. Dr. Vanhoutte has published over 500 original research papers, 474 book reviews, and authored or edited 3 books. In 2000 he was nominated for the Nobel Prize for his outstanding contributions to the field of cardiovascular disease.
Professor Barry H. Greenberg
    Dr. Greenberg is currently Professor of Medicine at UCSD School of Medicine and Director of the Advanced Heart Failure Treatment Program at UCSD. He is also a charter member of the UCSD/Salk Institute of Molecular Medicine. He is a founding member and former vice president of the Heart Failure Society of America. He is a member of the advisory board for Neucardin™’s clinical trials. Dr. Greenberg leads an active research program investigating basic mechanisms and new treatment methods involved in heart failure. He serves on the Editorial Board for many famous cardiology journals and is an editor of Congestive Heart Failure and an associate editor of the Journal of the American College of Cardiology. Dr. Greenberg has been consistently selected as one of the "Best Doctors in America" for many years.
Professor Inder Anand
    Dr. Anand received his Ph.D. degree in cardiovascular physiology from Oxford University and is a professor at the University of Minnesota. He is the chairman of the heart failure group. He is an advisor for global clinical trials for Neucardin™. He has been active in designing and conducting clinical trials in heart failure over the last twenty years. He has been a principal investigator in over 50 heart failure clinical trials, and a member of steering and end-point committees on several of these international trials. He is a member of the editorial board for several scientific journals and has authored over 300 publications with over 1,000 citations of his published work.
Tony Chen, J.D.
Patent Lawyer
    Mr. Chen received his bachelor degree in cellular biology at the University of Science and Technology of China and his Juris Doctor degree from Harvard Law School. He is the partner of Jones Day, a renowned US-based law firm, as well as a member of the life science advisory board of Shanghai Pudong Government.
Professor Charles Antzelevitch
    Dr. Antzelevitch is the Executive Director and Director of Research of the Masonic Medical Research Laboratory (MMRL), He also holds an academic appointment as Professor of Pharmacology at the SUNY Health Science Center at Syracuse and an endowed chair in Experimental Cardiology (Gordon K. Moe Scholar) at the MMRL. Throughout his professional life, Dr. Antzelevitch has been at the forefront of experimental cardiology research, particularly the electrical function of the heart and factors that contribute to the development of abnormal rhythms. He is an internationally renowned authority in these areas and is an often invited to speak at international symposia and to present seminars at medical schools and institutes throughout the world. He has authored more than 265 original papers and 3 books, and more than 230 abstracts.
Clinical Trials Recruiting Participants